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Background. Small mothers against decapentaplegic (SMAD)4 and SMAD7 are key regulatory components in the
immunosuppressive transforming growth factor- (TGF-) β signaling pathway, which is defective in inﬂammatory bowel disease
(IBD). SMAD4 may play an important role in the pathogenesis of IBD as indicated in experimental models of colitis. Aims. To
examine the ileal expression levels of SMAD4 and to correlate these with CD disease activity. Methods. The material comprised
29 CD patients (13 with active disease, 16 in remission) and 9 asymptomatic patients referred for ileocolonoscopy as part of an
adenoma surveillance program serving as controls. Patients were examined with ileocolonoscopy. Corresponding ileal biopsies
were obtained for histological analysis and assessment of SMAD4 and SMAD7 protein expression by immunohistochemistry
(IHC). Results. The protein expression of SMAD4 was signiﬁcantly downregulated in ileal tissue sections from CD patients
as compared to healthy controls (p < 0 001). Further, luminal SMAD4 expression was inversely correlated with endoscopic
(rs = −0 315; p = 0 05) and histopathological activity (rs = −0 40; p = 0 013). Conclusions. The SMAD4 epithelial protein level
was markedly downregulated in CD patients and inversely correlated with disease activity. This may contribute to defective
mucosal TGF-β signaling in active IBD.
1. Introduction
The disruption of the colonic epithelial barrier is associ-
ated with inﬂammatory bowel disease (IBD) [1], and
achievement of mucosal healing is an important treatment
goal [2], since it is associated with sustained steroid-free
clinical remission and reduced risk of surgery [3]. Once
the epithelial barrier is disrupted, commensal bacteria
and their products may cross the intestinal wall [4, 5]
and give rise to an inappropriate immune response, which
perpetuates chronic inﬂammation.
A key anti-inﬂammatory cytokine is transforming growth
factor- (TGF-) β [6], which is constitutively expressed in
the gut by intestinal epithelial cells (IECs), ﬁbroblasts, and
lamina propria mononuclear cells (LPMCs) [7]. The TGF-β
level is elevated in IBD [8], but TGF-β signaling has been
proposed defective in IBD and thus counteracts the increased
TGF-β levels [9]. A phase 2 study showed that reduction of
the TGF-β signaling inhibitor SMAD7 by administration of
an antisense oligonucleotide (mongersen) resulted in a sig-
niﬁcant improvement in Crohn’s disease (CD) activity com-
pared with placebo [10, 11]. Mongersen has also been shown
to improve Simple Endoscopic Score for Crohn’s Disease
(SES-CD) [12]. However, a recent phase 3 study has been
terminated early due to negative results in an interim analy-
sis. The downstream signaling protein SMAD4, a common
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SMAD, which is required for full activation of TGF-β signal-
ing, is the only mammalian common SMAD and may be
equally important in IBD. SMAD4 forms a multi-SMAD
complex with phosphorylated and thus activated SMAD2
and SMAD3. This complex translocates to the nucleus and
acts as a transcription factor complex on a variety of genes
[6]. Of note, Smad4+/− mice are more prone to develop acute
inﬂammation as seen in a chemically-induced colitis model
[13]. Mice carrying a deletion of the Smad4 gene selectively
in T cells develop strong gastrointestinal inﬂammation and
eventually cancer [14]. Hence, SMAD4 and SMAD7 have
opposing eﬀects on the TGF-β signaling pathway; however,
little is currently known about the role of SMAD4 in patients
with IBD.
The primary aim of this study was to examine the protein
expression levels of SMAD4 in mucosal biopsies obtained
from the terminal ileum of patients with CD and to correlate
the expression levels with CD activity.
2. Materials and Methods
2.1. Patients. Patients referred for ileocolonoscopy at the
Copenhagen University Hospital Herlev and Gentofte were
prospectively enrolled in the study. Twenty-nine patients
with CD were included and comprised 16 in remission and
13 with active disease. Active disease was deﬁned using
SES-CD score as described by Daperno et al. [15]. The
patients were classiﬁed as being in endoscopic remission, if
SES-CD< 3 in the terminal ileum and colon [15]. Relapse
was deﬁned as need for treatment escalation or surgical
intervention during the follow-up period.
Further, histopathological changes as described by
D’Haens et al. [16] were scored blindly by an experienced
pathologist (LBR) and categorized as normal, with chronic
inactive inﬂammation or chronic active inﬂammation. The
control group consisted of 9 asymptomatic patients referred
for ileocolonoscopy as part of an adenoma surveillance pro-
gram, where biopsies were obtained from endoscopically
normal terminal ileum and conﬁrmed by histology. Patients
below 18 years, pregnant or breastfeeding, and with impaired
renal function were excluded from the study. All patients
provided written informed consent to participate in the
study. The groups were equally distributed in terms of sex,
but the individuals in the control group were older than the
CD patients. Due to scarce biopsy material, only 11 patients
with active disease and 9 patients in remission were analyzed
for SMAD7 expression. Table 1 summarizes the patient
characteristics and medication of the CD patients. The study
was approved by the Scientiﬁc Ethics Committee of the Cap-
ital Region of Denmark (September 17, 2012, protocol num-
ber H-1-2012-089) and the Danish Data Protection Agency
(September 13, 2012, protocol number HEH.750.89-32) and
was registered in http://clinicaltrials.gov (NCT01684514).
The study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki as reﬂected in a prior approval
by the institution’s human research committee.
2.2. Endoscopy. Ileocolonoscopy was performed with a white
light confocal laser endomicroscope (CLE) colonoscope
(EC-3837CILK, Pentax Medicals) due to a parallel study
on CLE in CD. SES-CD assessment was performed in
the terminal ileum and colon [15]. Biopsy specimens were
obtained at identical sites in the terminal ileum.
2.3. Immunohistochemistry (IHC). The biopsy specimens
were formalin ﬁxed and paraﬃn-embedded (FFPE). From
each biopsy, 3μm sections were cut and stained with haema-
toxylin and eosin. The biopsy specimens were assessed in a
blinded manner by LBR and scored as described by D’Haens
et al. [16]. Sections from the FFPE terminal ileum biopsies
were pretreated by deparaﬃnization, rehydration, and
epitope retrieval in one step (high pH) by the use of “Pre-
treatment Module” (PT-link; Dako, Glostrup, Denmark)
according to the manufacturer’s instruction. IHC staining
was performed using the “Dako Autostainer Link” and with
the commercially available kit (EnVision Flex; Dako). Slides
were counterstained with Mayers haematoxylin before
viewing. The antibodies used were SMAD4 ((B-8) : sc7966,
dilution 1 : 1000; Santa Cruz Biotechnology) and SMAD7
((Z8-B) : sc-101152, dilution 1 : 100; Santa Cruz Biotechnol-
ogy). Ductal breast carcinoma tissue was used as positive
control for SMAD4 and SMAD7. Isotype controls were run
in parallel as negative controls. IHC was done in one proce-
dure for all sections to ensure equal staining. The laboratory
has been accredited according to the “Danish Healthcare
Quality Programme” and participates in NordicQC (Nordic
Immunohistochemical Quality Control).
The evaluation of the stained slides was performed by
semiquantitative scoring of the intensity of the staining on
the villi (luminal) and crypts (basal) for SMAD4. SMAD7
was given one score for the percentage of stained cells in
the lamina propria. The SMAD4 immunoreactivity was
graded from 0–3 according to the intensity: 0 for absent, 1
for weak, 2 for moderate, and 3 for strong staining. The
intensity scoring was performed blindly by LBR.
2.4. Statistics. Possible diﬀerences between the groups were
tested with one-way ANOVA (continuous variables) and
Fisher’s exact test (binary variables). The median with
interquartile range (IQR) was presented. Kruskal-Wallis test
was used to determine diﬀerences between the IHC scores
of SMAD4 and SMAD7 in active CD, remission CD, and
controls. Spearman’s rho rank test was used for correla-
tions between endoscopic SES-CD, histopathological score,
SMAD4, and SMAD7. A two-sided p value< 0.05 was con-
sidered signiﬁcant. For all statistics, IBM SPSS Statistics 22
(SPSS, Chicago, USA) and GraphPad Prism version 7.02
(GraphPad Software Inc., California, USA) were used.
3. Results
3.1. SMAD4 Is Markedly Downregulated in Ileal Epithelial
Cells from CD Patients. Figure 1 shows representative
SMAD4 stainings on small bowel sections from CD patients
with active disease or in remission as well as from a control.
In active disease (Figure 1(a)), there is a pronounced down-
regulation of the SMAD4 protein expression in particular
on the apical epithelial surface (luminal SMAD4) compared
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with controls (Figure 1(c)). In contrary, SMAD4 staining is
moderate in remission but still decreased compared with
control (Figure 1(b)). Accordingly, the median luminal
SMAD4 protein expression level was signiﬁcantly decreased
in sections from CD patients compared to controls (p <
0 0001) (Figure 1(d)). In contrast, basal SMAD4 expression
was moderately but signiﬁcantly downregulated in the CD
patients compared to controls (p = 0 032) (Figure 1(e)).
Notably, the strongest staining for SMAD4 in the control
group was in the IECs, albeit immune cells in the lamina
propria also expressed SMAD4 (Figure 1(c)). In 3 (24%) of
the CD patients, luminal SMAD4 was completely absent both
in the IECs and LPMCs. SMAD7 was weakly to moderately
expressed in the epithelial cells in some patients but strongly
expressed in the LPMCs (Figures 2(a) and 2(b)). While there
was no signiﬁcant upregulation of SMAD7 in patients with
active disease compared with controls, CD patients in remis-
sion had a signiﬁcantly lower amount of SMAD7-positive
LPMCs compared with CD patients with active disease and
controls (p = 0 039) (Figure 2(d)). There was no signiﬁcant
correlation neither between SMAD7 and luminal SMAD4
expression (rs = 0 312; p = 0 106) nor between SMAD7 and
basal SMAD4 expression (rs = 0 210; p = 0 284).
3.2. Luminal SMAD4 but Not SMAD7 Expression Is Inversely
Correlated to Disease Activity. When correlated to disease
activity, we found that luminal SMAD4 expression was
signiﬁcantly inversely correlated to the severity of the disease
in terms of SES-CD and histopathological activity. Basal
SMAD4 expression was not correlated to SES-CD or histo-
pathological activity. Moreover, SMAD7 expression did not
correlate to SES-CD or histopathological activity (Table 2).
To summarize, luminal SMAD4 was downregulated in
CD patients and was inversely correlated to disease activity.
SMAD7 expression was not signiﬁcantly changed in CD
patients compared with controls but was signiﬁcantly down-
regulated in CD patients in remission.
During a mean follow-up of 71 weeks, 15 (54%) CD
patients relapsed after a mean period of 18 weeks. Seven
patients with relapse and 2 in remission were examined with
repeat ileocolonoscopy and collection of ileal biopsies during
the follow-up period. Interestingly, we observed an increased
Table 1: Patient characteristics.
Active CD Remission CD Controls p value
Number (%) 13 (34) 16 (42) 9 (24)
Female (%) 6 (46) 7 (44) 3 (33) 0.839
Age (median (IQR)) 38 (29.00–55.50) 44 (35.75–52.75) 75 (56.50–76.50) 0.001
Age at diagnosis
A1 (below 16 years) (%) 0 0 —
A2 (17–40 years) (%) 10 (77) 12 (75) —
A3 (above 40 years) (%) 3 (23) 4 (25) —
Location
L1 ileal (%) 10 (77) 4 (25) —
L2 colonic (%) 0 11 (69) —
L3 ileocolonic (%) 3 (23) 1 (6) —
Behavior
B1 nonstricturing, nonpenetrating (%) 2 (15) 10 (63) —
B2 stricturing (%) 10 (77) 2 (13) —
B3 penetrating (%) 1 (8) 4 (25) —
Previous intestinal resection related to CD
Small bowel (%) 0 0 —
Colorectal (%) 0 0 —
Small bowel and colon (%) 4 (29) 2 (10) —
Disease localization of active luminal CD (SES-CD> 2)
Small bowel (%) 10 (77) 0 —
Colorectal (%) 0 (0) 0 —
Small bowel and colon (%) 3 (23) 0 —
Ongoing medical treatment ∗
TNF inhibitors (%) 1 (7) 9 (56) —
Azathioprine (%) 4 (31) 9 (56) —
Corticosteroids (%) 2 (14) 1 (6) —
CD: Crohn’s disease; SES-CD: Simple Endoscopic Score for Crohn’s Disease. Montreal classiﬁcation was used for classiﬁcation of disease behavior. ∗In the aCD
group, 1 patient received both TNF inhibitors and azathioprine; in the rCD group, 4 patients received both TNF inhibitors and azathioprine, while 1 patient
received corticosteroids and azathioprine.
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Figure 1: Immunohistochemical staining of SMAD4 on ileal biopsies. The luminal SMAD4 protein expression (brown color) was decreased
in CD patients with active disease (aCD) (a, b) compared to CD patients in remission (rCD) (c, d) and healthy controls (e, f). Original
magniﬁcation ×20 (a, c, and e) and ×40 (b, d, and f). Luminal (g) and basal (h) SMAD4 was signiﬁcantly downregulated in CD patients
compared to controls. Median and IQR are shown.
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Figure 2: Immunohistochemical staining of SMAD7 on ileal biopsies. The lamina propria mononuclear cell (LPMC) SMAD7 protein
expression (brown color) was similar in CD patients with active disease (aCD) (a, b) compared to controls (e, f). SMAD7 was
downregulated in CD patients in remission (rCD) (c, d). Original magniﬁcation ×20 (a, c, and e) and ×40 (b, d, and f). SMAD
downregulation in CD patients in remission was signiﬁcant compared to controls and active CD (g). Median and IQR are shown.
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SMAD4 expression in the two patients in long-term remis-
sion (luminal score increased to 2) while SMAD4 expression
remained low in the seven patients who relapsed (luminal
score 0 or 1). This observation needs to be conﬁrmed in a
larger group of patients but indicates that the SMAD4 level
is dynamic and related to disease activity.
4. Discussion
This is an explorative and hypothesis-generating study, with
the novel primary ﬁnding that ileal SMAD4 protein expres-
sion level is substantially decreased in patients with active
CD. Thus, our data point to an immunosuppressive defect
in CD patients, which may be reversed for patients in long-
term remission. We found the strongest expression of
SMAD4 in normal IECs, and the most pronounced downreg-
ulation on the apical (i.e., luminal) surface in CD patients
with active disease. Sixteen out of 29 (55%) CD patients were
in histopathological remission when endoscopy was per-
formed the ﬁrst time. They still exhibited low (50%) or
moderate (50%) luminal SMAD4 expression. Thus, the
SMAD4 defect is not reversed with medical treatment includ-
ing anti-tumor necrosis factor- (TNF-) α antibodies, which
some patients received to obtain remission (Table 1). There
was no correlation between a low level of SMAD4 and the
time of relapse, but follow-up biopsies in nine patients
showed that the SMAD4 level was increased (luminal score
2) in the seven patients who stayed in remission but
remained low (luminal score 0 or 1) in the two who relapsed.
The major SMAD4 defect was shown in the luminal, fully
matured IECs as well as LPMCs. The IECs are functioning
not only as a simple barrier but also as the front line of
defense, orchestrating the immune response due to the ability
of IECs to produce a variety of molecules including cytokines
[17], antimicrobial peptides [18, 19], and proteinases [20].
The consequence of an impaired TGF-β signaling in the IECs
may inﬂuence not only repression of the immune response
but also healing of ulcers, as TGF-β has a prominent role in
wound healing [21].
We speculate that the SMAD4 decrease is an early
defect in CD, and it would be interesting to pinpoint when
and how early it occurs. The SMAD4 expression is regu-
lated by several microRNAs (miRNAs) [22–26] as well as
on a posttranslational level [27, 28]. A plausible explanation
on how the SMAD4 level is reduced could be that the acti-
vation of toll-like receptors on the epithelial cell surface by
intestinal bacteria induces a signaling cascade through
nuclear factor-kappa B, which in turn upregulates a variety
of miRNAs, and some of these may inhibit the production
of SMAD4 protein and thus induce a sustained SMAD4
downregulation [29]. In this context, it is interesting that
the existing transformed human IEC cell line models are
all either SMAD4 negative or TGF-β receptor II negative
[30]. The profound downregulation of TGF-β signaling in
human IEC cell lines may be explained by the fact that
TGFBRII mutations are highly represented in tumors with
microsatellite instability and SMAD4 is mutated in more
than half of colorectal tumors without microsatellite
instability [6].
Previous ﬁndings have demonstrated an upregulation
of SMAD7 especially in the LPMCs in active CD patients
[31]. We were unable to detect an increased SMAD7
expression level in CD patients with active disease com-
pared with controls. But interestingly, we observed a signiﬁ-
cant downregulation in CD patients in remission compared
with patients with active disease. These ﬁndings support
the eﬀects of mongersen therapy, as shown previously
[31]. One could speculate that the lack of eﬀect of monger-
sen in the phase 3 study is due to a low level of SMAD4
that is still present in CD patients with active disease. A
combination of knockdown of SMAD7 as well as induction
of SMAD4 would be more eﬃcient in the restoration of full
TGF-β signaling.
The limitations in this study include only a small cohort
was analyzed. Also, only the terminal ileum was investigated;
inclusion of the colon would be an interesting study in the
future. Most of the patients (69%) in remission had previous
disease activity in the colon, and the control group was signif-
icantly older than the CD patients. A study with an analysis
of the LPMC population, as well as inclusion of a larger
number of patients in the follow-up study, is warranted. Only
the semiquantitative analysis IHC was used. Quantitative
analyses (quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR) and western blotting) have been per-
formed. However, the material analyzed was lysates of
cellular fractions (epithelial and intraepithelial cells) of the
whole biopsy. We found that SMAD4 downregulation was
mainly seen at the apical surface of the biopsy, which
accounts for a small area of the biopsy (Supplementary
Figure 1). Thus, biochemical analyses of the whole biopsy
do not reﬂect the ﬁnding seen by IHC (data not shown).
Future protocols should include qRT-PCR and proteomic
analysis on laser microdissected cells.
In conclusion, we have shown that the SMAD4 protein
level is markedly downregulated in particular in the mature
IECs from CD patients, and this is signiﬁcantly and inversely
correlated with disease activity. The ileal SMAD7 protein
level was downregulated in CD patients in remission. This
may contribute to maintain chronic inﬂammation due to
insuﬃcient TGF-β activity.
Table 2: Correlations.
p value Correlation coeﬃcient rs
Luminal SMAD4
SES-CD 0.001 −0.530
Histopathological activity 0.013 −0.399
Basal SMAD4
SES-CD 0.190 −0.217
Histopathological activity 0.281 −0.179
SMAD7
SES-CD 0.143 0.284
Histopathological activity 0.294 0.205
Correlation of disease activity to SMAD4 and SMAD7. Spearman’s rho
correlation was made on the entire cohort.
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